JPWO2020174283A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020174283A5 JPWO2020174283A5 JP2021549617A JP2021549617A JPWO2020174283A5 JP WO2020174283 A5 JPWO2020174283 A5 JP WO2020174283A5 JP 2021549617 A JP2021549617 A JP 2021549617A JP 2021549617 A JP2021549617 A JP 2021549617A JP WO2020174283 A5 JPWO2020174283 A5 JP WO2020174283A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- alkyl
- group
- hydrogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 201000009273 Endometriosis Diseases 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 claims 2
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010002519 Prolactin Receptors Proteins 0.000 claims 2
- 102100029000 Prolactin receptor Human genes 0.000 claims 2
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 claims 2
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- 102000005602 Aldo-Keto Reductases Human genes 0.000 claims 1
- 108010084469 Aldo-Keto Reductases Proteins 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 102000011367 Prostanoid EP4 receptors Human genes 0.000 claims 1
- 108050001693 Prostanoid EP4 receptors Proteins 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810163P | 2019-02-25 | 2019-02-25 | |
| US62/810,163 | 2019-02-25 | ||
| PCT/IB2020/000160 WO2020174283A1 (en) | 2019-02-25 | 2020-02-24 | Treatment with p2x3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521955A JP2022521955A (ja) | 2022-04-13 |
| JPWO2020174283A5 true JPWO2020174283A5 (enExample) | 2023-02-24 |
| JP7578602B2 JP7578602B2 (ja) | 2024-11-06 |
Family
ID=72239247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549617A Active JP7578602B2 (ja) | 2019-02-25 | 2020-02-24 | Ｐ２ｘ３修飾薬での治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12485125B2 (enExample) |
| EP (1) | EP3930722A4 (enExample) |
| JP (1) | JP7578602B2 (enExample) |
| CN (1) | CN113727716A (enExample) |
| AU (1) | AU2020228760A1 (enExample) |
| CA (1) | CA3131312A1 (enExample) |
| IL (1) | IL285772A (enExample) |
| WO (1) | WO2020174283A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113727716A (zh) | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | 采用p2x3调节剂的治疗 |
| BR112022015858A2 (pt) * | 2020-02-14 | 2022-10-25 | Bellus Health Cough Inc | Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometriose |
| WO2021244634A1 (zh) * | 2020-06-05 | 2021-12-09 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2023020156A1 (zh) * | 2021-08-20 | 2023-02-23 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
| GB202212749D0 (en) * | 2022-09-01 | 2022-10-19 | Gesynta Pharma Ab | New uses |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH503559A (de) | 1969-02-26 | 1971-02-28 | Arx Paul Von | Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| AU2002305236A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent |
| SE0102808D0 (sv) | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| ES2380709T3 (es) | 2004-09-24 | 2012-05-17 | Astrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, su preparación y usos |
| MX2007013595A (es) | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
| AU2010322478B2 (en) | 2009-11-18 | 2013-11-14 | Glaxosmithkline Intellectual Property (No. 3) Limited | Benzoimidazole compounds and uses thereof |
| WO2012158117A1 (en) * | 2011-05-17 | 2012-11-22 | Astrazeneca Ab | Combination therapies for treating pain |
| WO2013002584A2 (ko) | 2011-06-28 | 2013-01-03 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| WO2014117274A1 (en) * | 2013-01-31 | 2014-08-07 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| EP4194251A1 (en) | 2013-08-15 | 2023-06-14 | Volvo Truck Corporation | Method and arrangement for balancing an energy storage system |
| SG11201601145RA (en) | 2013-08-23 | 2016-03-30 | Afferent Pharmaceuticals Inc | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
| JP6544665B2 (ja) * | 2014-12-09 | 2019-07-17 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | １，３−チアゾール−２−イル置換ベンズアミド |
| EP3355889B1 (en) | 2015-09-29 | 2023-02-15 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| RU2761439C2 (ru) | 2016-03-14 | 2021-12-08 | Эфферент Фармасьютикалз Инк. | Пиримидины, их варианты и применение |
| WO2017161342A1 (en) | 2016-03-17 | 2017-09-21 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through rnaset2 |
| MX2019003710A (es) | 2016-09-30 | 2019-06-24 | Asana Biosciences Llc | Compuestos y metodos de p2x3 y/o p2x2/3. |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| CN113302191A (zh) * | 2018-11-13 | 2021-08-24 | 贝卢斯医疗咳嗽病公司 | 取代的咪唑并吡啶化合物的结晶形式及其作为p2x3调节剂的用途 |
| CA3121162A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| KR102797127B1 (ko) | 2018-12-29 | 2025-04-21 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도 |
| CN113727716A (zh) | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | 采用p2x3调节剂的治疗 |
| BR112022015858A2 (pt) | 2020-02-14 | 2022-10-25 | Bellus Health Cough Inc | Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometriose |
| MX2022009765A (es) | 2020-02-14 | 2022-09-09 | Bellus Health Cough Inc | Preparacion de un antagonista del purinorreceptor 3 p2x (p2x3). |
-
2020
- 2020-02-24 CN CN202080031287.8A patent/CN113727716A/zh active Pending
- 2020-02-24 CA CA3131312A patent/CA3131312A1/en active Pending
- 2020-02-24 JP JP2021549617A patent/JP7578602B2/ja active Active
- 2020-02-24 WO PCT/IB2020/000160 patent/WO2020174283A1/en not_active Ceased
- 2020-02-24 EP EP20763699.4A patent/EP3930722A4/en active Pending
- 2020-02-24 AU AU2020228760A patent/AU2020228760A1/en not_active Abandoned
-
2021
- 2021-08-22 IL IL285772A patent/IL285772A/en unknown
- 2021-08-30 US US17/461,988 patent/US12485125B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2241285T3 (es) | Derivados bencimidazol como moduladores de ige. | |
| ES2705001T3 (es) | Tratamiento de neoplasias hematológicas con un anticuerpo anti-CXCR4 | |
| RU2018144427A (ru) | Способы лечения ar+ рака молочной железы | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2012515787A5 (enExample) | ||
| JP2009541209A5 (enExample) | ||
| CN1325304A (zh) | 用于治疗偏头痛的5ht1受体激动剂和甲氧氯普胺 | |
| HRP20100366T1 (hr) | Antagonisti receptora progesterona | |
| RU2009131454A (ru) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств | |
| EP2455081A1 (en) | S1P1 receptor agonists for use in the treatment of crohn's disease | |
| JP2003519228A5 (enExample) | ||
| JP2006501306A5 (enExample) | ||
| JP2009507073A5 (enExample) | ||
| US20020107244A1 (en) | Combination treatment for depression | |
| JPWO2020174283A5 (enExample) | ||
| JP2024530204A (ja) | Ｂ細胞悪性腫瘍の治療に使用するための組成物 | |
| KR20020090153A (ko) | 알콜중독 또는 알콜 의존을 위한 배합 치료 | |
| JP2009501745A5 (enExample) | ||
| CA2312989A1 (en) | Combination therapy for the treatment of migraine | |
| AU2017328999A1 (en) | Combination of FXR agonists | |
| WO2021194991A1 (en) | Use of losmapimod for treatment of covid-19 | |
| JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
| JP2010513489A5 (enExample) | ||
| JPWO2020018551A5 (enExample) | ||
| CN1859846A (zh) | 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用 |